Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Complete Surgical Metastasectomy for Renal Cell Carcinoma in the Post-cytokine Era.

Lyon TD, Thompson RH, Shah PH, Lohse CM, Boorjian SA, Costello BA, Cheville JC, Leibovich BC.

J Urol. 2019 Aug 8:101097JU0000000000000488. doi: 10.1097/JU.0000000000000488. [Epub ahead of print]

PMID:
31393812
2.

Long-Term Outcomes of Patients With Low Grade Cystic Renal Epithelial Neoplasms.

Westerman ME, Cheville JC, Lohse CM, Sharma V, Boorjian SA, Leibovich BC, Thompson RH.

Urology. 2019 Jul 26. pii: S0090-4295(19)30652-1. doi: 10.1016/j.urology.2019.07.017. [Epub ahead of print]

PMID:
31356826
3.

Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.

Gupta S, Swanson AA, Chen YB, Lopez T, Milosevic D, Kipp BR, Leibovich BC, Thompson RH, Herrera-Hernandez L, Cheville JC, Jimenez RE.

Hum Pathol. 2019 Sep;91:114-122. doi: 10.1016/j.humpath.2019.07.004. Epub 2019 Jul 9.

PMID:
31299266
4.

Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.

Eur Urol Oncol. 2019 Jul;2(4):390-396. doi: 10.1016/j.euo.2018.09.004. Epub 2018 Sep 28.

PMID:
31277775
5.

Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?

Bhindi B, Lohse CM, Schulte PJ, Mason RJ, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH.

Eur Urol. 2019 Sep;76(3):e67-e68. doi: 10.1016/j.eururo.2019.05.033. Epub 2019 Jun 2. No abstract available.

PMID:
31167750
6.

Sarcopenia and Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.

Lyon TD, Frank I, Takahashi N, Boorjian SA, Moynagh MR, Shah PH, Tarrell RF, Cheville JC, Viers BR, Tollefson MK.

Clin Genitourin Cancer. 2019 Jun;17(3):216-222.e5. doi: 10.1016/j.clgc.2019.03.007. Epub 2019 Mar 25.

PMID:
31060857
7.

Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses.

Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH.

Eur Urol. 2019 Aug;76(2):244-251. doi: 10.1016/j.eururo.2019.04.026. Epub 2019 May 3.

PMID:
31060824
8.

JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.

Gupta S, Cheville JC, Jungbluth AA, Zhang Y, Zhang L, Chen YB, Tickoo SK, Fine SW, Gopalan A, Al-Ahmadie HA, Sirintrapun SJ, Blum KA, Lohse CM, Hakimi AA, Thompson RH, Leibovich BC, Berger MF, Arcila ME, Ross DS, Ladanyi M, Antonescu CR, Reuter VE.

Mod Pathol. 2019 Sep;32(9):1344-1358. doi: 10.1038/s41379-019-0269-x. Epub 2019 Apr 17.

PMID:
30996253
9.

An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set.

DeRycke MS, Larson MC, Nair AA, McDonnell SK, French AJ, Tillmans LS, Riska SM, Baheti S, Fogarty ZC, Larson NB, O'Brien DR, Cheville JC, Wang L, Schaid DJ, Thibodeau SN.

PLoS One. 2019 Apr 8;14(4):e0214588. doi: 10.1371/journal.pone.0214588. eCollection 2019.

10.

A comparison of adult rhabdomyosarcoma and high-grade neuroendocrine carcinoma of the urinary bladder reveals novel PPP1R12A fusions in rhabdomyosarcoma.

Gupta S, Sosa CP, Kosari F, Folpe A, Bhinge KN, Yang L, Agahi A, Johnson SH, Frank I, Boorjian SA, Hansel DE, Al-Ahmadie HA, Reuter VE, Vasmatzis G, Jimenez RE, Herrera-Hernandez L, Cheville JC.

Hum Pathol. 2019 Jun;88:48-59. doi: 10.1016/j.humpath.2019.03.007. Epub 2019 Apr 1.

PMID:
30946934
11.

Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Tarrel R, Quevedo FJ, Cheville JC, Karnes RJ.

World J Urol. 2019 Feb 25. doi: 10.1007/s00345-019-02689-8. [Epub ahead of print]

PMID:
30805684
12.

George M. Farrow, MD: A Tribute.

Cheville JC, Keeney GL, Gaffey TA.

Am J Surg Pathol. 2019 Mar;43(3):432-433. doi: 10.1097/PAS.0000000000000942. No abstract available.

PMID:
30747783
13.

Comprehensive characterization of perioperative reoperation following radical cystectomy.

Lyon TD, Boorjian SA, Shah PH, Tarrell R, Cheville JC, Frank I, Karnes RJ, Thompson RH, Tollefson MK.

Urol Oncol. 2019 Apr;37(4):292.e11-292.e17. doi: 10.1016/j.urolonc.2018.11.023. Epub 2019 Jan 22.

PMID:
30679081
14.

Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.

BJU Int. 2019 Jun;123(6):1011-1019. doi: 10.1111/bju.14612. Epub 2019 Jan 8.

PMID:
30623554
15.

Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer.

Vasmatzis G, Kosari F, Murphy SJ, Terra S, Kovtun IV, Harris FR, Zarei S, Smadbeck JB, Johnson SH, Gaitatzes AG, Therneau TM, Rangel LJ, Knudson RA, Greipp P, Sukov WR, Knutson DL, Kloft-Nelson SM, Karnes RJ, Cheville JC.

Mayo Clin Proc. 2019 Jan;94(1):27-36. doi: 10.1016/j.mayocp.2018.06.028.

PMID:
30611450
16.

Predicting Renal Function Outcomes After Partial and Radical Nephrectomy.

Bhindi B, Lohse CM, Schulte PJ, Mason RJ, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH.

Eur Urol. 2019 May;75(5):766-772. doi: 10.1016/j.eururo.2018.11.021. Epub 2018 Nov 23.

PMID:
30477983
17.

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.

Lyon TD, Frank I, Sharma V, Shah PH, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Cheville JC, Boorjian SA.

World J Urol. 2019 Aug;37(8):1605-1613. doi: 10.1007/s00345-018-2551-9. Epub 2018 Nov 3.

PMID:
30392012
18.

Enhanced mRNA FISH with compact quantum dots.

Liu Y, Le P, Lim SJ, Ma L, Sarkar S, Han Z, Murphy SJ, Kosari F, Vasmatzis G, Cheville JC, Smith AM.

Nat Commun. 2018 Oct 26;9(1):4461. doi: 10.1038/s41467-018-06740-x.

19.

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G.

J Thorac Oncol. 2019 Feb;14(2):276-287. doi: 10.1016/j.jtho.2018.10.001. Epub 2018 Oct 10.

20.

Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.

Gershman B, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC.

Eur Urol. 2018 Dec;74(6):825-832. doi: 10.1016/j.eururo.2018.08.028. Epub 2018 Sep 24.

PMID:
30262341
21.

Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era.

Lyon TD, Gershman B, Shah PH, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC.

Urol Oncol. 2018 Nov;36(11):499.e1-499.e7. doi: 10.1016/j.urolonc.2018.08.008. Epub 2018 Sep 15.

PMID:
30228096
22.

Prognostic evaluation of perinephric fat, renal sinus fat, and renal vein invasion for patients with pathological stage T3a clear-cell renal cell carcinoma.

Shah PH, Lyon TD, Lohse CM, Cheville JC, Leibovich BC, Boorjian SA, Thompson RH.

BJU Int. 2019 Feb;123(2):270-276. doi: 10.1111/bju.14523. Epub 2018 Sep 9.

PMID:
30113768
23.

The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.

Bhindi B, Thompson RH, Lohse CM, Mason RJ, Frank I, Costello BA, Potretzke AM, Hartman RP, Potretzke TA, Boorjian SA, Cheville JC, Leibovich BC.

Eur Urol. 2018 Oct;74(4):489-497. doi: 10.1016/j.eururo.2018.06.003. Epub 2018 Jul 13.

PMID:
30017400
24.

The Association of Aspirin Use with Survival Following Radical Cystectomy.

Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

J Urol. 2018 Nov;200(5):1014-1021. doi: 10.1016/j.juro.2018.05.119. Epub 2018 May 30.

PMID:
29857079
25.

Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists.

Zhang P, Schaefer-Klein J, Cheville JC, Vasmatzis G, Kovtun IV.

Oncotarget. 2018 May 11;9(36):24428-24442. doi: 10.18632/oncotarget.25319. eCollection 2018 May 11.

26.

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20.

Gupta S, Sahu D, Bomalaski JS, Frank I, Boorjian SA, Thapa P, Cheville JC, Hansel DE.

Endocr Pathol. 2018 Sep;29(3):236-241. doi: 10.1007/s12022-018-9516-9.

PMID:
29453600
27.

Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.

Leibovich BC, Lohse CM, Cheville JC, Zaid HB, Boorjian SA, Frank I, Thompson RH, Parker WP.

Eur Urol. 2018 May;73(5):772-780. doi: 10.1016/j.eururo.2018.01.005. Epub 2018 Feb 3.

PMID:
29398265
28.

Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Gearman DJ, Morlacco A, Cheville JC, Rangel LJ, Karnes RJ.

J Urol. 2018 May;199(5):1188-1195. doi: 10.1016/j.juro.2017.11.116. Epub 2017 Dec 7.

PMID:
29225057
29.

Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis.

Gershman B, Thompson RH, Boorjian SA, Larcher A, Capitanio U, Montorsi F, Carenzi C, Bertini R, Briganti A, Lohse CM, Cheville JC, Leibovich BC.

J Urol. 2018 May;199(5):1143-1148. doi: 10.1016/j.juro.2017.11.114. Epub 2017 Dec 7.

PMID:
29225056
30.

Perioperative Morbidity of Lymph Node Dissection for Renal Cell Carcinoma: A Propensity Score-based Analysis.

Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC.

Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30911-9. doi: 10.1016/j.eururo.2017.10.020. [Epub ahead of print]

PMID:
29132713
31.

Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.

Murphy SJ, Kosari F, Karnes RJ, Nasir A, Johnson SH, Gaitatzes AG, Smadbeck JB, Rangel LJ, Vasmatzis G, Cheville JC.

Cancer Res. 2017 Nov 15;77(22):6157-6167. doi: 10.1158/0008-5472.CAN-17-0529. Epub 2017 Nov 10.

32.

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.

Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M.

Int J Mol Sci. 2017 Nov 3;18(11). pii: E2326. doi: 10.3390/ijms18112326.

33.

Alcohol consumption, variability in alcohol dehydrogenase genes and risk of renal cell carcinoma.

Antwi SO, Eckel-Passow JE, Diehl ND, Serie DJ, Custer KM, Wu KJ, Cheville JC, Thiel DD, Leibovich BC, Parker AS.

Int J Cancer. 2018 Feb 15;142(4):747-756. doi: 10.1002/ijc.31103. Epub 2017 Oct 28. Erratum in: Int J Cancer. 2018 Sep 1;143(5):E6.

34.

Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.

Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS.

J Clin Oncol. 2017 Nov 10;35(32):3706-3713. doi: 10.1200/JCO.2017.73.3238. Epub 2017 Oct 4.

35.

Surgical Management and Oncologic Outcomes of Recurrent Venous Tumor Thrombus after Prior Nephrectomy for Renal Cell Carcinoma.

Parker WP, Boorjian SA, Zaid HB, Cheville JC, Leibovich BC, Thompson RH.

Eur Urol Focus. 2016 Dec 15;2(6):625-630. doi: 10.1016/j.euf.2016.05.003. Epub 2016 Jul 7.

PMID:
28723495
36.

Oncologic surveillance following radical cystectomy: an individualized risk-based approach.

Merrill SB, Boorjian SA, Thompson RH, Psutka SP, Cheville JC, Thapa P, Tollefson MK, Frank I.

World J Urol. 2017 Dec;35(12):1863-1869. doi: 10.1007/s00345-017-2068-7. Epub 2017 Jul 6.

PMID:
28685181
37.

Coffee consumption and risk of renal cell carcinoma.

Antwi SO, Eckel-Passow JE, Diehl ND, Serie DJ, Custer KM, Arnold ML, Wu KJ, Cheville JC, Thiel DD, Leibovich BC, Parker AS.

Cancer Causes Control. 2017 Aug;28(8):857-866. doi: 10.1007/s10552-017-0913-z. Epub 2017 Jun 24.

38.

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ.

JCI Insight. 2017 Jun 15;2(12). pii: 92688. doi: 10.1172/jci.insight.92688. eCollection 2017 Jun 15.

39.

Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.

Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

Eur Urol. 2017 Nov;72(5):660-664. doi: 10.1016/j.eururo.2017.05.016. Epub 2017 May 22.

PMID:
28545841
40.

Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?

Bhindi B, Lohse CM, Mason RJ, Westerman ME, Cheville JC, Tollefson MK, Boorjian SA, Thompson RH, Leibovich BC.

Urology. 2017 Nov;109:121-126. doi: 10.1016/j.urology.2017.04.010. Epub 2017 Apr 12.

PMID:
28412331
41.

Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy.

Yang DY, Thompson RH, Zaid HB, Lohse CM, Rule AD, Boorjian SA, Leibovich BC, Cheville JC, Tollefson MK.

J Urol. 2017 Oct;198(4):795-802. doi: 10.1016/j.juro.2017.04.016. Epub 2017 Apr 8.

PMID:
28396181
42.

TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.

Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, Costello BA, Leibovich BC, Thompson RH, Cheville JC, Sukov WR.

Mod Pathol. 2017 Jul;30(7):998-1012. doi: 10.1038/modpathol.2017.24. Epub 2017 Mar 24.

43.

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Eckel-Passow JE, Serie DJ, Cheville JC, Ho TH, Kapur P, Brugarolas J, Thompson RH, Leibovich BC, Kwon ED, Joseph RW, Parker AS.

BMC Urol. 2017 Mar 21;17(1):19. doi: 10.1186/s12894-017-0209-3.

44.

Genomic tests to guide prostate cancer management following diagnosis.

Colicchia M, Morlacco A, Cheville JC, Karnes RJ.

Expert Rev Mol Diagn. 2017 Apr;17(4):367-377. doi: 10.1080/14737159.2017.1302332. Epub 2017 Mar 13. Review.

PMID:
28277880
45.

Prognostic significance of lymphatic, vascular and perineural invasion for bladder cancer patients treated by radical cystectomy.

Muppa P, Gupta S, Frank I, Boorjian SA, Karnes RJ, Thompson RH, Thapa P, Tarrell RF, Herrera Hernandez LP, Jimenez RE, Cheville JC.

Pathology. 2017 Apr;49(3):259-266. doi: 10.1016/j.pathol.2016.12.347. Epub 2017 Mar 1.

PMID:
28259358
46.

Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.

Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC.

Eur Urol. 2017 Aug;72(2):300-306. doi: 10.1016/j.eururo.2016.12.027. Epub 2017 Jan 13.

PMID:
28094055
47.

Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.

Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00018. Epub 2017 Aug 1.

48.

Clinical and surgical management of a congenital Type II split cord malformation presenting with progressive cranial neuropathies: case report.

Maloney PR, Murphy ME, Sullan MJ, Van Abel KM, Cofer SA, Cheville JC, Wetjen NM.

J Neurosurg Pediatr. 2017 Mar;19(3):349-353. doi: 10.3171/2016.9.PEDS15661. Epub 2016 Dec 23.

PMID:
28009225
49.

Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.

Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, Parker AS, Eckel-Passow JE.

Ann Oncol. 2017 Mar 1;28(3):604-610. doi: 10.1093/annonc/mdw652.

50.

Patient factors associated with 30-day complications after partial nephrectomy: A contemporary update.

Zaid HB, Parker WP, Lohse CM, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH.

Urol Oncol. 2017 Apr;35(4):153.e1-153.e6. doi: 10.1016/j.urolonc.2016.11.001. Epub 2016 Dec 6.

PMID:
27939815

Supplemental Content

Loading ...
Support Center